Among these gene mutations, very few occurred frequently (TP53, MUC16, CTNNB1, TTN, ARID1A, PCLO, NBPF10, and CSMD1), which might explain the relatively poor prognosis and insufficient effective target-drug treatment for HCC. Here, PCLO is linked to hepatocellular carcinoma.